22 June 2023
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Annual General Meeting Results
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.
The total number of votes received on each resolution were as follows:
| | Voting For | Voting Against | | |||||
| Number of votesi | % | Number of votes | % | Total Votes | % ISC | Votes withheldii | ||
| Resolution 1 | To receive and adopt the annual report of the directors and the financial statements for the financial year ended 31 December 2022 and the report of the appointed auditors thereon. | 69,770,830 | 99.98% | 11,289 | 0.02% | 69,782,119 | 24.22% | 19,089 |
| Resolution 2 | To re-elect John Clarke as a Director of the Company, who retires by rotation in accordance with the Company's articles of association. | 69,751,950 | 99.96% | 26,170 | 0.04% | 69,778,120 | 24.22% | 23,089 |
| Resolution 3 | To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company. | 69,717,388 | 99.91% | 64,733 | 0.09% | 69,782,121 | 24.22% | 19,089 |
| Resolution 4 | To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company. | 69,720,243 | 99.91% | 61,879 | 0.09% | 69,782,122 | 24.22% | 19,089 |
| Resolution 5 | To authorise that the Directors of the Company are generally and unconditionally authorised for the purposes of section 551 Companies Act 2006 (the "CA 2006") to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company | 69,231,840 | 99.87% | 90,153 | 0.13% | 69,321,993 | 24.06% | 479,219 |
| Resolution 6iii | A Special Resolution, subject to the passing of Resolution 5 set out above, that authorises the Directors to allot equity securities (as defined in the CA 2006) for cash under the authority given by that resolution and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561 of the CA 2006 did not apply to any such allotment or sale, to be limited to £57,626 | 69,019,760 | 99.59% | 287,234 | 0.41% | 69,306,994 | 24.05% | 494,219 |
| Resolution 7 | A Special Resolution, subject to the passing of Resolution 6 set out above, that authorises the Directors, in addition to any authority granted under Resolution 6, to allot equity securities (as defined in the CA 2006) for cash under the authority given by that resolution and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561 of the CA 2006 did not apply to any such allotment or sale, limited to £57,626, with such authority to be used only for the purposes of financing | 69,019,007 | 99.57% | 298,988 | 0.43% | 69,317,995 | 24.06% | 483,219 |
ⁱ Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution
ⁱⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution
ⁱⁱⁱ Special Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 22 June 2023 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 288,133,957 ordinary shares of 0.2p each. The Company does not hold any shares in treasury
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted two Phase 3 studies using MED3000 in ED; FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
